Adenine Base Editing of APOE4 to APOE3 for Alzheimer's Prevention
📖 Wiki Page
idea705 wordssynced 2026-04-02
Base Editing for APOE4
Additional evidence sources:
Overview
Pathway / Mechanism Diagram
graph TD
A["APOE Gene"] --> B["APOE e2 (Protective)"]
A --> C["APOE e3 (Neutral)"]
A --> D["APOE e4 (Risk Factor)"]
D --> E["Impaired Abeta Clearance"]
D --> F["Enhanced Tau Phosphorylation"]
D --> G["BBB Dysfunction"]
D --> H["Reduced Lipid Transport"]
E --> I["Amyloid Accumulation"]
F --> J["Tangle Formation"]
G --> K["Neuroinflammation"]
H --> L["Impaired Synaptic Repair"]
I --> M["Neurodegeneration"]
J --> M
K --> M
L --> M
B --> N["Enhanced Abeta Clearance"]
N --> O["Reduced AD Risk"]
style D fill:#ef5350,color:#e0e0e0
style B fill:#1b5e20,color:#e0e0e0
style M fill:#ef5350,color:#e0e0e0
Gene Therapy for Neurodegeneration — Therapeutic approach
Base Editing Therapy — Therapeutic modality
AAV Delivery Methods — Vector choice
Actionable Next Steps
Preclinical Validation: Test base editing efficiency in APOE4 knock-in neuronal models
Delivery Optimization: Compare AAV versus lipid nanoparticle delivery for brain penetration
Safety Assessment: Evaluate off-target editing and immune responses in relevant models
Implementation Roadmap
Phase 1 (0-6 months): In vitro validation of base editing constructs in cell models
Phase 2 (6-18 months): Preclinical efficacy and toxicity studies in animal models
Phase 3 (18-36 months): IND-enabling studies and regulatory consultations
See Also
[Therapeutics Index — Comprehensive directory of therapeutic approaches](/content/therapeutics)
[Alzheimer's Disease Treatments — Current and emerging AD therapies](/content/treatments)
[Parkinson's Disease Treatments — Current and emerging PD therapies](/content/treatments)
[Neuroinflammation Mechanisms — Inflammatory pathways in neurodegeneration](/content/mechanisms)
[Mitochondrial Dysfunction — Energy metabolism impairment](/entities/mitochondria)
External Links
[ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
[Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
[Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
[NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources
References
[Gaudelli NM, Komor AC, Rees HA, et al, Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage (2017)](https://pubmed.ncbi.nlm.nih.gov/29160308/))
[Rees HA, Liu DR, Base editing: precision chemistry on the genome and transcriptome of living cells (2018)](https://pubmed.ncbi.nlm.nih.gov/30442934/))
[Yamazaki Y, Zhao N, Caulfield TR, et al, Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies (2019)](https://pubmed.ncbi.nlm.nih.gov/31367008/))
[Corder EH, Saunders AM, Strittmatter WJ, et al, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families (1993)](https://pubmed.ncbi.nlm.nih.gov/8346443/))
[Shi Y, Yamada K, Liddelow SA, et al, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy (2017)](https://pubmed.ncbi.nlm.nih.gov/28966368/))
[Arboleda-Velasquez JF, Lopera F, O'Hare M, et al, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report (2019)](https://pubmed.ncbi.nlm.nih.gov/31672369/))
[Barthélemy NR, Horie K, Sato C, Bhatt DK, Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32123386/))
[Musunuru K, Chadwick AC, Mizoguchi T, et al, In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates (2021)](https://pubmed.ncbi.nlm.nih.gov/33992038/))
[Levy JM, Yeh WH, Pendse N, et al, Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses (2020)](https://pubmed.ncbi.nlm.nih.gov/32895555/))
[Belloy ME, Napolioni V, Greicius MD, A quarter century of APOE and Alzheimer's disease: progress to date and the path forward (2019)](https://pubmed.ncbi.nlm.nih.gov/31727856/))
[Serrano-Pozo A, Das S, Bhatt DK, APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches (2021)](https://pubmed.ncbi.nlm.nih.gov/33986542/))